Skip to main content

Table 3 Pearson Phi correlations between PtGA and Pain, HAQ-DI, and FACIT-F outcomes at month 3 in csDMARD-IR patients

From: Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib

 

  N

Correlation coefficient

P value

a) Correlation with LDA (PtGA VAS score ≤ 20 mm)

Mild Pain (VAS score ≤ 20 mm)

 Tofacitinib 5 mg BID + csDMARDs

  695

0.74

< 0.0001

 Placebo + csDMARDs

  366

0.73

< 0.0001

Moderate Pain improvement (≥ 30% decrease from baseline)

 Tofacitinib 5 mg BID + csDMARDs

  692

0.42

< 0.0001

 Placebo + csDMARDs

  365

0.45

< 0.0001

Substantial Pain improvement (≥ 50% decrease from baseline)

 Tofacitinib 5 mg BID + csDMARDs

  692

0.55

< 0.0001

 Placebo + csDMARDs

  365

0.58

< 0.0001

HAQ-DI score ≥ normative value (≤ 0.25)

 Tofacitinib 5 mg BID + csDMARDs

  695

0.28

< 0.0001

 Placebo + csDMARDs

  366

0.24

< 0.0001

HAQ-DI change ≥ MCID (≥ 0.22 improvement from baseline)

 Tofacitinib 5 mg BID + csDMARDs

  693

0.18

< 0.0001

 Placebo + csDMARDs

  364

0.14

0.0064

FACIT-F score ≥ normative value (≥ 43.5)

 Tofacitinib 5 mg BID + csDMARDs

  694

0.35

< 0.0001

 Placebo + csDMARDs

  365

0.29

< 0.0001

FACIT-F change ≥ MCID (≥ 4.0 improvement from baseline)

 Tofacitinib 5 mg BID + csDMARDs

  693

0.13

0.0004

 Placebo + csDMARDs

  363

0.11

0.0413

b) Correlation with moderate PtGA improvement (≥ 30% decrease from baseline)

Mild Pain (VAS score ≤ 20 mm)

 Tofacitinib 5 mg BID + csDMARDs

  694

0.42

< 0.0001

 Placebo + csDMARDs

  365

0.42

< 0.0001

Moderate Pain improvement (≥ 30% decrease from baseline)

 Tofacitinib 5 mg BID + csDMARDs

  692

0.64

< 0.0001

 Placebo + csDMARDs

  365

0.55

< 0.0001

Substantial Pain improvement (≥ 50% decrease from baseline)

 Tofacitinib 5 mg BID + csDMARDs

  692

0.56

< 0.0001

 Placebo + csDMARDs

  365

0.55

< 0.0001

HAQ-DI score ≥ normative value (≤ 0.25)

 Tofacitinib 5 mg BID + csDMARDs

  694

0.13

0.0006

 Placebo + csDMARDs

  365

0.16

0.0029

HAQ-DI change ≥ MCID (≥ 0.22 improvement from baseline)

 Tofacitinib 5 mg BID + csDMARDs

  692

0.30

< 0.0001

 Placebo + csDMARDs

  364

0.30

< 0.0001

FACIT-F score ≥ normative value (≥ 43.5)

 Tofacitinib 5 mg BID + csDMARDs

  693

0.17

< 0.0001

 Placebo + csDMARDs

  364

0.18

0.0008

FACIT-F change ≥ MCID (≥ 4.0 improvement from baseline)

 Tofacitinib 5 mg BID + csDMARDs

  692

0.24

< 0.0001

 Placebo + csDMARDs

  363

0.26

<  0.0001

c) Correlation with substantial PtGA improvement (≥ 50% decrease from baseline)

Mild Pain (VAS score ≤ 20 mm)

 Tofacitinib 5 mg BID + csDMARDs

  694

0.55

< 0.0001

 Placebo + csDMARDs

  365

0.50

< 0.0001

Moderate Pain improvement (≥ 30% decrease from baseline)

 Tofacitinib 5 mg BID + csDMARDs

  692

0.59

< 0.0001

 Placebo + csDMARDs

  365

0.51

< 0.0001

Substantial Pain improvement (≥ 50% decrease from baseline)

 Tofacitinib 5 mg BID + csDMARDs

  692

0.68

< 0.0001

 Placebo + csDMARDs

  365

0.70

< 0.0001

HAQ-DI score ≥ normative value (≤ 0.25)

 Tofacitinib 5 mg BID + csDMARDs

  694

0.18

< 0.0001

 Placebo + csDMARDs

  365

0.13

0.0126

HAQ-DI change ≥ MCID (≥ 0.22 improvement from baseline)

 Tofacitinib 5 mg BID + csDMARDs

  692

0.29

< 0.0001

 Placebo + csDMARDs

  364

0.26

< 0.0001

FACIT-F score ≥ normative value (≥ 43.5)

 Tofacitinib 5 mg BID + csDMARDs

  693

0.23

< 0.0001

 Placebo + csDMARDs

  364

0.20

0.0001

FACIT-F change ≥ MCID (≥ 4.0 improvement from baseline)

 Tofacitinib 5 mg BID + csDMARDs

  692

0.26

< 0.0001

 Placebo + csDMARDs

  363

0.23

< 0.0001

  1. Generally, correlation coefficient values around 0.3, 0.5, and 0.7 are considered as weak, moderate, and strong positive linear correlations, respectively
  2. Abbreviations: BID twice daily, csDMARD conventional synthetic disease-modifying antirheumatic drug, FACIT-F Functional Assessment of Chronic Illness Therapy-Fatigue, HAQ-DI Health Assessment Questionnaire-Disability Index, IR inadequate responder, LDA low disease activity, MCID minimum clinically important difference, PtGA Patient Global Assessment of Disease Activity, VAS Visual Analog Scale